CHF Solutions Ships Aquadex Product to COVID-19 Specialty Center in Minnesota
May 01 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced that it has shipped Aquadex product to a specialty care
center designated for the most severe COVID-19 patients in
Minnesota.
“We continue to receive positive feedback from physicians and
medical staff who are using Aquadex therapy to treat patients
affected with COVID-19 throughout the country,” said John Erb, CEO
of CHF Solutions. “With these first shipments within
Minneapolis-St. Paul, we are pleased that the Aquadex therapy is
being used to help patients in our own community.”
Several hospitals across the country have included a simplified
ultrafiltration system, such as Aquadex therapy, into their
treatment protocol for fluid management for COVID-19 patients,
especially when dialysis equipment and staff are limited. This
simple, flexible and smart system allows for a 4:1 patient to nurse
ratio, versus a 1:1 ratio required by dialysis equipment. This
means that the nurse does not have to remain by the bedside for the
entire treatment, thereby preserving vital staff and equipment for
patients that do require dialysis.
A recent publication on fluid stewardship in critically ill
patients with COVID-19 from Baylor University Medical Center,
published April 16, 2020, identifies isolated ultrafiltration is an
“optimal strategy that primarily focuses on fluid extraction and
optimization of volume status” while loop diuretic use in
critically ill patients with positive fluid balance was associated
with prolonged mechanical ventilation. In addition, it states
“portable ultrafiltration devices could prove particularly helpful,
in that their extremely small extracorporeal volume will help avoid
a potential adverse hemodynamic impact in the critically ill.
Moreover, the predictability of the fluid extraction will make it
more likely to achieve the precise goal for the de-escalation
process.”1
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The
Aquadex SmartFlow system delivers clinically proven therapy using a
simple, flexible and smart method of removing excess fluid from
patients suffering from hypervolemia (fluid overload). The Aquadex
SmartFlow system is indicated for temporary (up to 8 hours) or
extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
the Aquadex system to treat patients affected with COVID-19.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1. Amir Kazory, Claudio Ronco & Peter A. McCullough (2020):
“SARS-CoV-2 (COVID-19) and intravascular volume management
strategies in the critically ill”, Baylor University Medical Center
Proceedings, DOI: 10.1080/08998280.2020.1754700.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024